Clinical trial
An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy
NCT05644392 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open, Single-arm, Single-centre Clinical Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours That Have Failed at Least One Prior Systemic Therapy
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 25, 2022
- Completion date
- November 25, 2025
- Enrollment
- 30 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
advanced biliary systemic tumours that has failed at least one prior systemic therapy